SRES-620-119
Submitted in the Senate, considered, and agreed to without amendment and with a preamble by Unanimous Consent. (consideration: CR S716; text: CR S711)
Sponsored by John Barrasso (R-WY)
What it does
This resolution designates February 28, 2026, as "Rare Disease Day." It is a symbolic, commemorative measure passed by the Senate through unanimous consent. It does not create any new programs, allocate funding, change existing law, or impose any requirements on any person or entity.
Who benefits
Patients living with rare diseases (estimated 30 million Americans), their families, and caregivers may benefit from increased public awareness. Rare disease advocacy organizations and patient groups gain a federally recognized platform. Researchers and pharmaceutical companies working on rare disease treatments may benefit from heightened public and legislative attention to the field.
Who is hurt
No group is materially harmed by this resolution. There are no costs, mandates, or restrictions imposed on any individual, organization, or government entity.
Supporters argue
Supporters argue that rare diseases — defined as conditions affecting fewer than 200,000 Americans — collectively affect an estimated 30 million people in the U.S., yet many receive little research funding or public attention due to their individual rarity. They contend that federal recognition through a designated day raises awareness, encourages research investment, and signals congressional commitment to a population that is often overlooked in mainstream health policy discussions.
Opponents argue
Opponents might argue that symbolic resolutions consume limited legislative time and floor resources without producing any tangible policy outcome for rare disease patients. They could contend that meaningful support for rare disease communities requires substantive action — such as increased NIH funding or expanded Orphan Drug Act incentives — rather than a commemorative designation that carries no legal or budgetary weight.